Avoro Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Avoro Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-664,000	Closed	-$120M	–	46
2021 Q3	$120M	Sell	664,000 -126,000	-16%	-$24.6M	1.89%	14
2021 Q2	$159M	Sell	790,000 -610,000	-44%	-$128M	2.77%	11
2021 Q1	$301M	Buy	+1,400,000	New	+$308M	5.2%	5

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Avoro Capital Advisors's VRTX Position: Q4 2021 in Review

Avoro Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 664,000 shares — an estimated $120M sold.

Avoro Capital Advisors first reported a position in VRTX in Q1 2021 and held it in 3 quarters. The position peaked at $301M in Q1 2021. 1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

Avoro Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Avoro Capital Advisors sold 664,000 Vertex Pharmaceuticals shares in Q4 2021, an estimated $120M.
Avoro Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Avoro Capital Advisors's Vertex Pharmaceuticals position peaked at $301M in Q1 2021.
1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Avoro Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.